AIM: Lung carcinoma is the most common malignancy and the leading cause of cancer deaths worldwide. Although clinical factors including age, performance status and stage influence the likelihood of benefit from and tolerability of chemotherapy, the genetic profile of individual patients may be an independent predictor of response and toxicity. The present study aimed to identify pharmacogenetic markers associated with clinical response and toxicity in patients with advanced non-small cell lung cancer (NSCLC) treated primarily with carboplatin and paclitaxel. MATERIALS & METHODS: Genomic DNA samples from 90 adult male patients diagnosed with stage IIIB/IV NSCLC were genotyped for SNPs in candidate genes of relevance to platinating agents and paclitaxel and analyzed for association with survival and toxicities in univariate and multivariate models. RESULTS: After adjusting for performance status and stage, SNPs in the drug transporters ABCB1 and ABCC1, as well as within NQO1 were associated with progression-free survival. With respect to hematological and nonhematological toxicities, SNPs in drug transporters (ABCB1 and ABCG2) were associated with thrombocytopenia, nausea and neutropenia, whereas SNPs in the DNA repair pathway genes ERCC4 and XPC were significantly associated with neutropenia and sensory neuropathy, respectively. CONCLUSION: Our study evaluated and identified SNPs in key candidate genes in platinating agent and taxane pathways associated with outcome and toxicity in advanced NSCLC. If validated in large prospective studies, these findings might provide opportunities to personalize therapeutic strategies.
AIM: Lung carcinoma is the most common malignancy and the leading cause of cancer deaths worldwide. Although clinical factors including age, performance status and stage influence the likelihood of benefit from and tolerability of chemotherapy, the genetic profile of individual patients may be an independent predictor of response and toxicity. The present study aimed to identify pharmacogenetic markers associated with clinical response and toxicity in patients with advanced non-small cell lung cancer (NSCLC) treated primarily with carboplatin and paclitaxel. MATERIALS & METHODS: Genomic DNA samples from 90 adult male patients diagnosed with stage IIIB/IV NSCLC were genotyped for SNPs in candidate genes of relevance to platinating agents and paclitaxel and analyzed for association with survival and toxicities in univariate and multivariate models. RESULTS: After adjusting for performance status and stage, SNPs in the drug transporters ABCB1 and ABCC1, as well as within NQO1 were associated with progression-free survival. With respect to hematological and nonhematological toxicities, SNPs in drug transporters (ABCB1 and ABCG2) were associated with thrombocytopenia, nausea and neutropenia, whereas SNPs in the DNA repair pathway genes ERCC4 and XPC were significantly associated with neutropenia and sensory neuropathy, respectively. CONCLUSION: Our study evaluated and identified SNPs in key candidate genes in platinating agent and taxane pathways associated with outcome and toxicity in advanced NSCLC. If validated in large prospective studies, these findings might provide opportunities to personalize therapeutic strategies.
Authors: A Soyama; Y Saito; N Hanioka; N Murayama; O Nakajima; N Katori; S Ishida; K Sai; S Ozawa; J I Sawada Journal: Biol Pharm Bull Date: 2001-12 Impact factor: 2.233
Authors: C Meijer; A Timmer; E G De Vries; J P Groten; A Knol; N Zwart; W A Dam; D T Sleijfer; N H Mulder Journal: Int J Cancer Date: 2000-03-15 Impact factor: 7.396
Authors: Xifeng Wu; Jian Gu; Tsung-Teh Wu; Stephen G Swisher; Zhongxin Liao; Arlene M Correa; Jun Liu; Carol J Etzel; Christopher I Amos; Maosheng Huang; Silvia S Chiang; Luke Milas; Walter N Hittelman; Jaffer A Ajani Journal: J Clin Oncol Date: 2006-06-19 Impact factor: 44.544
Authors: Charles Lu; Margaret R Spitz; Hua Zhao; Qiong Dong; Mylene Truong; Joe Y Chang; George R Blumenschein; Waun K Hong; Xifeng Wu Journal: Cancer Date: 2006-01-15 Impact factor: 6.860
Authors: Chava Kimchi-Sarfaty; Jung Mi Oh; In-Wha Kim; Zuben E Sauna; Anna Maria Calcagno; Suresh V Ambudkar; Michael M Gottesman Journal: Science Date: 2006-12-21 Impact factor: 47.728
Authors: U Peters; S Preisler-Adams; A Hebeisen; M Hahn; E Seifert; C Lanvers; A Heinecke; J Horst; H Jürgens; A Lamprecht-Dinnesen Journal: Anticancer Drugs Date: 2000-09 Impact factor: 2.248
Authors: S Sakano; T Wada; H Matsumoto; S Sugiyama; R Inoue; S Eguchi; H Ito; C Ohmi; H Matsuyama; K Naito Journal: Br J Cancer Date: 2006-08-01 Impact factor: 7.640
Authors: M Eileen Dolan; Omar El Charif; Heather E Wheeler; Eric R Gamazon; Shirin Ardeshir-Rouhani-Fard; Patrick Monahan; Darren R Feldman; Robert J Hamilton; David J Vaughn; Clair J Beard; Chunkit Fung; Jeri Kim; Sophie D Fossa; Daniel L Hertz; Taisei Mushiroda; Michiaki Kubo; Lawrence H Einhorn; Nancy J Cox; Lois B Travis Journal: Clin Cancer Res Date: 2017-06-13 Impact factor: 12.531
Authors: Kari L Bjornard; Laura S Gilchrist; Hiroto Inaba; Barthelemy Diouf; Marilyn J Hockenberry; Nina S Kadan-Lottick; Daniel C Bowers; M Eileen Dolan; Nicole J Ullrich; William E Evans; Kirsten K Ness Journal: Lancet Child Adolesc Health Date: 2018-09-01
Authors: Komal P Singh; Anand A Dhruva; Elena Flowers; Kord M Kober; Christine Miaskowski Journal: Crit Rev Oncol Hematol Date: 2017-11-20 Impact factor: 6.312
Authors: T Powrózek; R Mlak; P Krawczyk; I Homa; M Ciesielka; P Kozioł; M Prendecka; J Milanowski; T Małecka-Massalska Journal: Clin Transl Oncol Date: 2015-07-21 Impact factor: 3.405
Authors: Matthew R Trendowski; Omar El Charif; Paul C Dinh; Lois B Travis; M Eileen Dolan Journal: Clin Cancer Res Date: 2018-10-10 Impact factor: 12.531